Navigating Bispecific Therapies in Multiple Myeloma: Roadmap for Onboarding and Operationalization

A panel of academic and community practice pharmacists with experience using BsAb was convened to provide recommendations for operationalizing and managing BsAb therapy



Institutional integration & operationalization

- (i) P&T workflow
- (i) EHR & REMS
- Financial considerations



Patient selection

- (i) Inpatient
- (i) Outpatient



■ Key stakeholders¹

- **Physicians**
- Advanced practice providers
- **Pharmacists**
- Nursing
- Social work
- Critical care staff
- **Emergency department staff**
- Administrators



Administration

- (i) Drug admin/monitoring
- (i) Caregiver considerations





Management

CRS/ICANS (i) Other AEs **GPRC5D AEs**



AE, adverse event; BsAb, bispecific antibody; CRS, cytokine release syndrome; EHR, electronic health record; GPRC5D, G protein-coupled receptor family C group 5 member D; ICANS, Immune effector cell-associated neurotoxicity syndrome; MM, multiple myeloma; P&T, Pharmacy & Therapeutics; REMS, risk evaluation and mitigation strategy. 1. Mahmoudjafari Z, et al. Sept 2024; online first. Available here: https://doi.org/10.6004/jadpro.2024.15.8.15



Please click the (i) icons for additional information.



Confidential and proprietary information. J&J does not endorse or promote use of any specific guidelines. These are provided for information purpose only, in response to a medial information request. US-SFM-6739 January 2025. © Johnson & Johnson and its affiliates 2025. Provided in response to a medical information request; for informational purposes only; no further use permitted. Capitalized product names are trademarks of Johnson & Johnson and its affiliates.